| Document |
Document Title |
|
WO/2023/213837A1 |
The present invention relates to cyclic compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices containing said compounds.
|
|
WO/2023/172112A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising the compound.
|
|
WO/2023/168240A1 |
The present disclosure relates to compounds that are capable of inhibiting the ENPP1 gene and treating a variety of cardiac conditions. The disclosure further relates to methods of treating or preventing cardiac conditions, such as myoca...
|
|
WO/2023/158708A1 |
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...
|
|
WO/2023/143741A1 |
The invention relates to a new type of physiological cooling agents, coolant mixtures containing said agents, mixtures of the coolants with flavors, the use of said cooling agents, and consumer products and final preparations containing ...
|
|
WO/2023/144326A1 |
The invention relates to a new type of physiological cooling agents, coolant mixtures containing said agents, mixtures of the coolants with flavors, the use of said cooling agents, and consumer products and final preparations containing ...
|
|
WO/2023/146897A1 |
Described herein are selective HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular dis...
|
|
WO/2023/131277A1 |
The present application belongs to the technical field of medicines, relates to an NLRP3 inflammasome inhibitor and the uses thereof, and particularly relates to a compound represented by general formula (A) or a pharmaceutically accepta...
|
|
WO/2023/125716A1 |
Provided in the present invention are a class of quinoline compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided in the present invention are a compound as shown in formula ...
|
|
WO/2023/125801A1 |
The present invention provides a fluoranthene derivative, a photoelectric conversion element containing same, and a light-emitting element. The fluoranthene derivative of the present invention has a specific structure comprising a fluora...
|
|
WO/2023/097386A1 |
The present invention relates to selective HDAC6-inhibiting N-acylhydrazone compounds. More specifically, the present invention relates to N-acylhydrazone compounds of formula (I), and to the methods for producing same, compositions, kit...
|
|
WO/2023/019912A9 |
Benzotriazine dioxide represented by the following general formula (I), or a pharmaceutically acceptable salt or ester, hydrate, solvate or prodrug thereof. Also provided are a composition and a method for treating cancer.
|
|
WO/2023/078915A1 |
The present invention relates to Bis(hetero)aryl thioether (thio)amides derivatives and the uses thereof for controlling phytopathogenic microorganisms such as phytopathogenic fungi. It also relates to processes and intermediates for pre...
|
|
WO/2023/081232A1 |
The invention provides novel linkers, linker conjugates, and drug conjugates thereof comprising a targeting moiety, a linker moiety, and a drug moiety, wherein the drug moiety is conjugated to the linker which is conjugated to the target...
|
|
WO/2023/068084A1 |
The present invention provides: a liquid crystal alignment agent that makes it possible to obtain a liquid crystal alignment film having little variation (non-uniformity) in the twist angle of liquid crystals in the plane of the liquid c...
|
|
WO/2023/066377A1 |
A compound represented by formula (I), a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of the pharmaceutically acceptable salt thereof, a preparation method therefor and an application thereof. The nitrogen-co...
|
|
WO/2023/063906A1 |
This invention is directed to novel thioamide substituted piperazinyl-1,2,4-triazines and their potential for use in treatment of malignant diseases, such as cancer.
|
|
WO/2023/036934A1 |
The present invention relates to cyclopropyl-(hetero)aryl substituted ethylsulphonyl-pyridine derivatives of formula (I),wherein the variables are as defined in the description and in the claims, which can be used as antiparasitic agents...
|
|
WO/2023/028536A1 |
The present invention relates to novel compounds of Formula (I), wherein each R1, R2, R3, Y, and Z are as defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the proce...
|
|
WO/2023/023572A1 |
Provided are compounds having the structure of Formula One or Formula Two: Formula One, or Formula Two. Pesticidal compositions and their uses are disclosed. Also disclosed are methods of synthesis for compounds disclosed herein.
|
|
WO/2023/280246A1 |
Provided are an organic compound and an application thereof in an organic electronic device, particularly in an organic electroluminescent diode. The present invention also relates to an organic electronic device containing the organic c...
|
|
WO/2023/277594A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2022/263829A1 |
The invention relates to compounds or salts of Formula (I-a), Formula (I-b), Formula (I-c), Formula (I-d), Formula (II) and pharmaceutical compositions containing these compounds. The compounds may be inducers of α1-antitrypsin (A1AT), ...
|
|
WO/2022/262821A1 |
A diclazuril derivative and an application thereof, as well as a fungicide for combating plant diseases, are disclosed, relating to the field of pesticides and fungicides. The derivative has a structural formula represented by formula (I...
|
|
WO/2022/253936A1 |
The invention relates to novel compounds having the general formula Ib wherein R1, R2, R3, R4, R5 and Z are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2022/230912A1 |
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The present inventors hav...
|
|
WO/2022/218437A1 |
The present invention relates to a lamotrigine hydrate crystal form, a preparation method therefor and a composition containing same, and particularly relates to a lamotrigine hydrate form A, a preparation method therefor and a compositi...
|
|
WO/2022/184177A1 |
Disclosed in the present invention is an aromatic compound, a preparation method therefor, and an application thereof. The present invention provides a compound as represented by formula I or a pharmaceutically acceptable salt thereof. T...
|
|
WO/2022/109469A9 |
Provided are compounds and compositions that inhibit glucose-induced growth signaling and methods of using same. The compounds may be suitable to treat glycolytic cancers, such as, for example, esophageal squamous cell carcinoma (ESCC). ...
|
|
WO/2022/068915A1 |
Provided are a 6-oxo-1,6-dihydropyridazin derivative, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a 6-oxo-1,6-dihydropyridazin derivative as shown by general formu...
|
|
WO/2022/059700A1 |
The present invention provides a triazine compound salt that has an aldosterone synthase inhibitory effect and is useful as a medicine, in particular, an agent for preventing or treating primary aldosteronism and the like, a crystal, and...
|
|
WO/2022/053028A1 |
Disclosed are a series of 1,2,4-triazine-3,5(2H,4H)-diketone compounds and an application thereof. Specifically disclosed are a compound represented by formula (III) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/037650A1 |
Provided herein are bridged bicyclic Compounds A and B or their pharmaceutically acceptable salts, which are as inhibitors of Bruton's tyrosine kinase (BTK) and its C481 mutant. Also provided are methods for preparing Compounds A and B o...
|
|
WO/2022/037617A1 |
A compound represented by structural formula (I) and a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing them, capable of being used as agonists of a thyroid hormone receptor -β, capable of being used ...
|
|
WO/2022/031838A1 |
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...
|
|
WO/2022/026285A1 |
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing influenza. The compounds are cap-dependent en...
|
|
WO/2022/007752A1 |
The present invention relates to the field of chemical medicines, and particularly to a new crystal form of a free base and dihydrochloride of benzamide compounds, and a preparation method therefor. Provided in the present invention are ...
|
|
WO/2022/006433A1 |
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...
|
|
WO/2021/228734A1 |
The present disclosure relates to triazine and pyrimidine (thio)amide compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.
|
|
WO/2021/224680A1 |
Compounds that are mammalian metabolites of an agonist of G-protein-coupled receptor 1.39 (GPR139), intermediates used in the synthesis of such metabolites, pharmaceutical compositions comprising such metabolites, and the use of such met...
|
|
WO/2021/186406A1 |
The present invention provides a co-crystal of sulfentrazone and a triazinone herbicide and process for preparation thereof. The present invention also provides an agrochemical composition comprising said co-crystal and process of prepar...
|
|
WO/2021/165818A1 |
The present invention relates to a novel chemical process for the synthesis of the compound 2- fluoro-N-methyl-4-[7-quinolin-6-yl-methyl)-imidazo[1,2-b][1,
2,4]triazin-2yl]benzamide.
|
|
WO/2021/143706A1 |
The application relates to a compound of Formula (I') or (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutica...
|
|
WO/2021/117809A1 |
According to the present invention, a light-emitting material formed from a compound comprising a naphthotriazole structure and/or a naphthotriazine structure has superior light-emitting properties.
|
|
WO/2021/096948A1 |
The disclosure relates to compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, incl...
|
|
WO/2021/093377A1 |
In order to improve the device performance of an organic electroluminescent device, particularly the light extraction efficiency, the present application provides an organic electroluminescent device comprising a light extraction layer, ...
|
|
WO/2021/057791A1 |
Provided are a chemical compound as a thyroid hormone Beta receptor agonist and a use thereof, further comprising a pharmaceutical composition containing the chemical compound. The chemical compound or pharmaceutical composition can be u...
|
|
WO/2021/043185A1 |
Provided herein is a compound as a thyroid hormone β receptor agonist and use thereof. It further relates to a pharmaceutical composition comprising the compound. The compound or the pharmaceutical composition can be used in the manufac...
|
|
WO/2021/032648A1 |
Bile acid derivatives, methods of manufacture thereof, and uses thereof are disclosed herein. The bile acid derivatives have demonstrated potential as therapeutics for treating liver disease.
|
|
WO/2020/251972A1 |
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamil...
|
